"Eyes Wide Open" - ACHAT - OC 12€ (vs 11,7€)
Nous actualisons notre modèle ce qui nous conduit à ajuster nos estimations de ventes de Vyzulta (latanoprostène bunod), Zerviate (AC-170) et à intégrer NCX 4251 et NCX 470. Trois principaux enjeux se présentent cette année : (i) l’approbation de son candidat le plus avancé Vyzulta que nous anticipons pour le T3 17 (24 août), (ii) l’approbation de Zerviate que nous prévoyons pour fin T3/début T4 17 et (iii) le lancement de 2 nouvelles études de phase II fin 2017/début 2018. Nous maintenons notre recommandation ACHAT avec un OC de 12€ (vs 11,7€ préc.).Nicox is engaged in the ophthalmic market. Co. markets several ophthalmic products in the United States and Europe with a portfolio of therapies and diagnostic tools that can help people to enhance their sight. Co. has developed naproxcinod, the first member of the Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents, for the treatment of the signs and symptoms of osteoarthritis. Beyond naproxcinod, Co. has a pipeline containing multiple nitric oxide-donating NCEs, which are in clinical development with partners for the treatment of diseases, such as hypertension, glaucoma and Chronic Obstructive Pulmonary Disease (COPD).
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.